EFFICIENCY OF ALTERNATIVE THERAPY IN PERIMENOPAUSAL AND POSTMENOPAUSAL WOMEN


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Objective. To evaluate the efficiency and safety of using the dietary supplement amberen in relieving vasomotor and psychosomatic disorders in perimenopausal and postmenopausal women. Subjects and methods. A randomized double-blind placebo-controlled trial was conducted among 42-60-year-old women with vasomotor and psychosomatic symptoms of menopause. Physical examination and questionnaire survey using Green’s test and Spielberger-Hanin test were done; the plasma levels of gonadotropins, estradiol, leptin, and apolipoproteins were determined. Results. The investigation enrolled 104 women who were randomized into 2 groups. The Green test revealed a statistically significant (p < 0.05) improvement in patients who took amberen in terms of 13 of 21 menopause symptoms. During and after its use, the levels of estradiol, gonadotropins, and leptin were significantly changed, the mean values of weight and waist circumference decreased in the patients. The Spielberger-Hanin test showed that amberen could stabilize the patients’ mental status with significantly reduced anxiety, enhanced resistance to stress, and improved adaptability. Comparative analysis of the measurements of vital signs and blood and urine tests revealed that amberen had a negative effect on the patients. Conclusion. The perimenopausal and postmenopausal use of amberen may be considered to be the method of choice in relieving the symptoms of menopause for women who have contraindications or who do not desire hormone therapy.

Texto integral

Acesso é fechado

Sobre autores

Irina Kuznetsova

I.M. Sechenov First Moscow State Medical University

MD, Professor, Women’s Health Research Institute, Research Center Moscow, Elanskogo str. 2, bld. 1, Russia

Yulia Uspenskaya

I.M. Sechenov First Moscow State Medical University

MD, Women’s Health Research Institute, Research Center Moscow, Elanskogo str. 2, bld. 1, Russia

Natalya Borisova

I.M. Sechenov First Moscow State Medical University

PhD, University Clinical Hospital Two Russia, Moscow, B. Pirogovskaya str. 19, bld. 1-3

Elvira Zhukova

I.M. Sechenov First Moscow State Medical University

PhD, University Clinical Hospital Two Russia, Moscow, B. Pirogovskaya str. 19, bld. 1-3

Nadezhda Berdnikova

I.M. Sechenov First Moscow State Medical University

MD, PhD, Department of Clinical Pharmacology and Internal Propedeutics Russia, Moscow, Yauzskaya str. 11

Yuri Gusak

Academician I.P. Pavlov Ryazan State Medical University

MD, Department Ryazan 390026, Vysokovoltnaya str. 9, Russia

Bibliografia

  1. Whiteley J., Di Bonaventura M.C., Wagner J.-S., Alvir J., Shah S. The impact of menopausal symptoms on quality of life, productivity, and economic outcomes. J. Womens Health (Larchmt.) 2013; 22(11): 983-90.
  2. Wieder-Huszla S., Szkup M., Jurczak A., Samochowiec A., Samochowiec J., Stanislawska M. et al. Effects of socio-demographic, personality and medical factors on quality of life of postmenopausal women. Int. J. Environ. Res. Publ. Health. 2014; 11(7): 6692-708.
  3. Williams R.E., Kalilani L., DiBenedetti D.B., Zhou X., Granger A.L., Fehnel S.E. et al. Frequency and severity of vasomotor symptoms among peri- and postmenopausal women in the United States. Climacteric. 2008; 11(1): 32-43.
  4. Rapkin A.J. Vasomotor symptoms in menopause: physiologic condition and central nervous system approaches to treatment. Am. J. Obstet. Gynecol. 2007; 196(2): 97-106.
  5. North American Menopause Society. The 2012 hormone therapy position statement: The North American Menopause Society. Menopause. 2012; 19(3): 257-71.
  6. Cho G.J., Lee J.H., Park H.T., Shin J.H., Hong S.C., Kim T. et al. Postmenopausal status according to years since menopause as an independent risk factor for the metabolic syndrome. Menopause. 2008; 15(3): 524-9.
  7. Sperling L.S., Mechanick J.I., Neeland I.J., Herrick C.J., Després J.P., Ndumele C.E. et al. The cardiometabolic health alliance: working toward a new care model for the metabolic syndrome. J. Am. Coll. Cardiol. 2015; 66(9): 1050-67.
  8. de Villiers T.J., Pines A., Panay N., Gambacciani M., Archer D.F., Baber R.J. et al. Updated 2013 IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric. 2013; 16(3): 316-37.
  9. Sood R., Faubion S.S., Kuhle C.L., Thielen J.M., Shuster L.T. Prescribing menopausal hormone therapy: an evidence-based approach. Int. J. Womens Health. 2014; 6(1): 47-57.
  10. Hill D.A., Hill S.R. Counseling patients about hormone therapy and alternatives for menopausal symptoms. Am. Fam. Physician. 2010; 82(7): 801-7.
  11. Oseni T., Patel R., Pyle J., Jordan V.C. Selective estrogen receptor modulators and phytoestrogens. Planta Med. 2008; 74(13): 1656-65.
  12. Loprinzi C.L., Qin R., Balcueva E.P., Flynn K.A., Rowland K.M. Jr., Graham D.L. et al. Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1. J. Clin. Oncol. 2010; 28(4): 641-7.
  13. Evans M., Elliott J.G., Sharma P., Berman R., Guthrie N. The effect of synthetic genistein on menopause symptom management in healthy postmenopausal women: a multi-center, randomized, placebo-controlled study. Maturitas. 2011; 68(2): 189-96.
  14. Chen T.T., Maevsky E.I., Uchitel M.L. Maintenance of homeostasis in the aging hypothalamus: the central and peripheral roles of succinate. Front. Endocrinol. (Lausanne). 2015; 6: 7.
  15. Maevsky E.I., Peskov A.B., Uchitel M.L., Pogorelov A.G., Saharova N.Y., Vihlyantseva E.F. et al. A succinate-based composition reverses menopausal symptoms without sex hormone replacement therapy. Adv. Gerontol. 2008; 21(2): 298-305.
  16. Harlow S.D., Gass M., Hall J.E., Lobo R., Maki P., Rebar R.W. et al.; STRAW 10 Collaborative Group. Executive summary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging reproductive aging. Menopause. 2012; 19(4): 387-95.
  17. Ziv-Gal A., Flaws J.A. Factors that may influence the experience of hot flushes by healthy middle-aged women. J. Womens Health (Larchmt). 2010; 19(10): 1905-14.
  18. Freedman R.R. Menopausal hot flashes: mechanisms, endocrinology, treatment. J. Steroid Biochem. Mol. Biol. 2014; 142: 115-20.
  19. Schilling C., Gallicchio L., Miller S.R., Langenberg P., Zacur H., Flaws J.A. Genetic polymorphisms, hormone levels, and hot flashes in midlife women. Maturitas. 2007; 57(2): 120-31.
  20. Sinchak K., Wagner E.J. Estradiol signaling in the regulation of reproduction and energy balance. Front. Neuroendocrinol. 2012; 33(4): 342-63.
  21. Skurnick J.H., Weiss G., Goldsmith L.T., Santoro N., Crawford S. Longitudinal changes in hypothalamic and ovarian function in perimenopausal women with anovulatory cycles: relationship with vasomotor symptoms. Fertil. Steril. 2009; 91(4): 1127-34.
  22. Toffoletto S., Lanzenberger R., Gingnell M., Sundström-Poromaa I., Comasco E. Emotional and cognitive functional imaging of estrogen and progesterone effects in the female human brain: a systematic review. Psychoneuroendocrinology. 2014; 50: 28-52.
  23. Long J., He P., Shen Y., Li R. New evidence of mitochondria dysfunction in the female Alzheimer’s brain: deficiency of estrogen receptor-β. J. Alzheimers. Dis. 2012; 30(3): 545-58.
  24. Markham A., Bains R., Franklin P., Spedding M. Changes in mitochondrial function are pivotal in neurodegenerative and psychiatric disorders: how important is BDNF? Br. J. Pharmacol. 2014; 171(8): 2206-29.
  25. Velarde M.C. Pleiotropic actions of estrogen: a mitochondrial matter. Physiol. Genomics. 2013; 45(3): 106-9.
  26. Sowers M., Zheng H., Tomey K., Karvonen-Gutierrez C., Jannausch M., Li X. et al. Changes in body composition in women over six years at midlife: ovarian and chronological aging. J. Clin. Endocrinol. Metab. 2007; 92(3): 895-901.
  27. Scarpulla R.C. Transcriptional paradigms in mammalian mitochondrial biogenesis and function. Physiol. Rev. 2008; 88(2): 611-32.
  28. Ossellame L.D., Blacker T.S., Duchen M.R. Cellular and molecular mechanisms of mitochondrial function. Best Pract. Res. Clin. Endocrinol. Metab. 2012; 26(6): 711-23.
  29. Fischer-Posovszky P., Wabitsch M., Hochberg Z. Endocrinology of adipose tissue - an update. Horm. Metab. Res. 2007; 39(5): 314-21.
  30. Soni A.C., Conroy M.B., Mackey R.H., Kuller L.H. Ghrelin, leptin, adiponectin, and insulin levels and concurrent and future weight change in overweight postmenopausal women. Menopause. 2011; 18(3): 296-301.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2016

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies